Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer

Despite recent advances in therapy for non-small cell lung cancer (NSCLC), the prognosis for patients with metastatic disease who progress after prior therapy remains poor. Heat shock protein 90 (HSP90) is a molecular chaperone which facilitates protein trafficking, stabilization, and folding. HSP90 is induced in stress states including cancer [1]. HSP90 mediates numerous oncogenic driver proteins important in NSCLC pathogenesis including epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) [2].

Source: Lung Cancer - May 20, 2019 Category: Cancer & Oncology Authors: Zorawar S. Noor, Jonathan W. Goldman, William E. Lawler, Bijoy Telivala, Fadi Braiteh, Brian A. DiCarlo, Kathleen Kennedy, Brad Adams, Xiaoyan Wang, Benjamin Jones, Dennis J. Slamon, Edward B. Garon Source Type: research